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Triple-negative breast cancer (TNBC), characterised by the minimal expression of 
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor-2 (HER-2), is an aggressive clinical phenotype. Its expression profile means it 
is not amenable to hormone therapy or HER-2 directed treatments with systemic 
treatment options limited to cytotoxic chemotherapy. There is therefore an unmet need 
for new targeted treatments for this cancer subtype. Transcription factor c-Myc (Myc) is 
frequently deregulated in these cases and is implicated in breast cancer development and 
progression. Omomyc is a peptide able to interfere with the protein-protein interactions 
of Myc, inhibiting transcriptional activation of its target genes. Here I report on the use 
of a new cell penetrating peptide (CPP), 1746, to deliver Omomyc to TNBC cells and on 
a truncated version of the Omomyc peptide (Omi) linked to 1746 (1746-Omi) and the 
traditional CPP Penetratin (Penetratin-Omi). I found 1746-Omomyc reduced the viability 
of TNBC cells overexpressing Myc by reducing proliferation. The truncated peptides 
were not as potent but demonstrated greater selectivity towards cancer cells. Penetratin-
Omi had a greater activity than 1746-Omi and reduced cell viability primarily through 
cell death rather than reduced proliferation. The effect of 1746-Omomyc and Penetratin-
Omi on the regulation of selected downstream Myc targets was determined by qRT-PCR 
and was consistent with but does not confirm Myc inhibition. This demonstrates the 
potential of 1746-Omomyc as an effective Myc inhibitor in TNBC. The shortening of 
Omomyc’s sequence reduced the peptides activity with much higher concentrations of 
1746-Omi and Penetratin-Omi required to effect cancer cell viability. The mechanism of 
action of Penetratin-Omi also differed from 1746-Omomyc, indicating the possibility of 
a cargo-dependent cytotoxicity at high concentrations. Improving the design of the 
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Triple-negative breast cancers (TNBCs) are those lacking overexpression of the estrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER-2) [1]. These are three of the most common receptors known to fuel breast cancer 
growth and are the targets of hormone and drug therapies. With no effective targeted 
treatment available, systemic treatment for patients with TNBC is limited to 
chemotherapeutical approaches which lack selectivity and often have undesirable side 
effects. Non-targeted chemotherapy drugs may also be limited in their ability to penetrate 
tumours, leading to drug resistance [2]. These aggressive malignancies are associated 
with resistance to chemotherapy, metastases, high rates of recurrence and mortality [1]. 
There is thus a great need for new targeted therapies to treat this breast cancer subtype. 
 
The majority of TNBCs are classified as basal-like tumours, which are associated with 
overexpression and copy number amplification of the oncogenic transcription factor c-
Myc (Myc) [3]. Myc is a non-redundant driver of cancer proliferation and is involved in, 
angiogenesis, cellular metabolism and resistance to apoptosis [4]. Transcription factors 
are not easily targeted with conventional drugs as they lack small molecule binding 
pockets. However, they often have highly conserved protein-protein interactions with 
binding partners and co-factors, which are essential for transcriptional activity [5]. 
Targeted interference with the protein-protein interactions of oncogenic transcription 
factors such as Myc may be a useful strategy to inhibit cancers such as TNBCs that are 
refractory to current treatments. 
 
Omomyc is a protein designed to interfere selectively with the protein-protein interactions 




protein has demonstrated the ability to eradicate cancer in several animal models [7, 8]. 
There is also evidence that the effects of Omomyc induced Myc inhibition in normal cells 
are mild and reversible [9]. Omomyc shows great potential as an anti-cancer agent. On 
its own, however, it lacks the ability to penetrate cells. Cellular and nuclear penetration 
are essential for the protein to reach its targets. Conjugation of Omomyc to a Cell 
Penetrating Peptide (CPP) could be a useful strategy to aid in its internalisation as CPPs 
are able to mediate the internalisation of molecules with low permeability into cells. 
Another barrier to the potential therapeutic usefulness of the Omomyc protein is its large 
size. It may be beneficial to produce a truncated version of the protein. This would open 
up the technological possibilities for its production and modification with potential 














2. Literature Review 
2.1 Triple-Negative Breast Cancer  
2.1.1 Overview 
Breast cancer is the most common cancer in women worldwide with over 1.6 million new 
cases diagnosed each year [10]. The prevalence of triple-negative breast cancers can vary 
in different populations but are reported to account for 15 to 20% of all breast cancer 
cases [11]. Gene expression profiling studies have identified at least six intrinsic 
molecular subtypes of breast cancer including luminal A, luminal B, normal breast-like, 
HER2 enriched, claudin-low and basal-like breast cancers [12]. The majority of TNBCs 
are of the basal-like subtype [13]. Basal-like breast cancers are a heterogeneous group 
that express genes and proteins usually found in basal or myoepithelial cells of the normal 
breast tissue [14]. They are associated with an aggressive phenotype, high histological 
grade, poor patient prognosis, and high rates of recurrence and metastasis [15]. Tumours 
of the basal-like subtype have more frequently overexpress Myc in comparison to the 
other subtypes [3, 16]. This overexpression has been shown to promote changes in cellular 
proliferation, differentiation, cell cycle progression, growth, metabolism, DNA 
replication, cell adhesion and metastasis [17]. 
 
As well as basal-like tumours, a substantial number of TNBCs have also been found to 
be of the more recently discovered claudin-low intrinsic subtype of breast cancer [18]. 
Claudin-low tumours are more enriched in epithelial-to-mesenchymal transition features, 
immune system responses, and stem-cell associated biological processes [19]. They are 
the most undifferentiated tumours along the mammary epithelial hierarchy. Tumours of 
the claudin-low subtype are reported to have lower expression of Myc than basal-like 
tumours, but higher expression of epidermal growth factor receptor (EGFR) and other 




2.1.2 Treatment and Research for TNBC 
Due to the absence of ER, PR and HER-2 overexpression in TNBCs, hormone therapy 
and HER-2 directed therapies are not useful treatment options for patients with these 
tumours. Systemic treatment is therefore limited to cytotoxic chemotherapy. Although 
TNBCs have a good initial response to chemotherapy, an early complete response does 
not correlate with overall survival as the risk of relapse in the first 3 to 5 years is 
significantly higher than with hormone receptor positive types of breast cancer [21]. For 
patients with residual cancer post chemotherapy, those with TNBCs also had a worse 
prognosis than those with the other subtypes [22]. It is of interest that tumour cells that 
do survive chemotherapy show features similar to the claudin-low subtype of breast 
cancer [23]. 
 
Several strategies to treat TNBC which aim to inhibit different targets or processes are 
being investigated. Currently, the key strategy is the development of Poly (ADP-Ribose) 
Polymerase (PARP) inhibitors designed to target cells with defective DNA repair 
mechanisms. Several PARP Inhibitors are currently being evaluated in Phase I or II 
clinical trials as a single agent or more commonly in combination therapies, with the aim 
of increasing sensitivity to chemotherapy or radiotherapy [24]. Other strategies have 
included the use of angiogenesis inhibitors such as Bevacizumab, a monoclonal antibody 
directed against vascular endothelial growth factor. Bevacizumab is used in combination 
therapies for those with metastatic HER-2 negative breast cancers but has not been shown 
to increase overall survival in Phase III clinical trials [25]. EGFR inhibitors such as 
Cetuximab have also been trialled in combination therapies for the treatment of TNBC 
but have again shown only modest results [26, 27]. Another approach has been the use of 
SRC-family kinase inhibitors such as Dasatinib. This was also shown to have a very 




also been trialled in combination therapies for patients with TNBC. Everolimus did not 
improve clinical response rates, however, and was associated with more adverse events 
[29]. It is clear there is still an unmet need to develop effective targeted treatments for 
patients with TNBC. Myc’s non-redundant role in cancer proliferation and its associations 
with the TNBC subtype makes inhibition of this oncogenic transcription factor a 
promising strategy. 
 
2.2 What is Myc? 
2.2.1 The Role of Myc 
The Myc protein has been shown through microarray studies to directly or indirectly 
influence the expression of up to 15% of all genes [30]. It is a key regulator involved in 
controlling a large range of cellular process including cell growth and division, apoptosis, 
cellular differentiation, angiogenesis, cell adhesion, cellular metabolism and motility 
[30]. Myc levels are low in quiescent cells, with levels rapidly increasing upon entry into 
the cell cycle and then declining to remain at a basal level in cycling cells [31].  
 
Myc drives transcription via the recruitment of co-factors to target gene promoters [32]. 
It is involved in cellular proliferation and controls the progression from the G1 to S-phase 
of the cell cycle via activation of downstream targets such as cyclin E/Cdk2, and 
repressing cyclin-dependent kinase (Cdk) inhibitor p21 [33, 34]. Cellular proliferation is 
also facilitated by Myc’s activation of cyclin D1, Cdk4, Cdc25A, E2F1 and E2F2 [35] 
Paradoxically, as well as promoting proliferation, Myc also acts as a tumour suppressor, 
with high levels of Myc sensitising cells to a range of pro-apoptotic stimuli [36]. A 
significant portion of Myc’s activity is cell type specific. However, a core set of target 




involved in biomass accumulation through ribosome biogenesis and RNA processing 
[37]. 
 
Myc has also been found to play an important role in stem cell biology and is involved in 
maintaining pluripotency and self-renewal in embryonic stem cells [38]. In 2006 it was 
named as one of the four Yamanaka factors needed to produce induced pluripotent stem 
cells (iPSCs) [39]. Since that time Myc has been found to be non-essential for iPSC 
production, although its inclusion greatly improves the efficiency [40]. 
 
2.2.2 Structure and Mechanism of action of the Myc Protein 
The Myc protein contains a transcriptional activation domain at its amino-terminus and a 
100 amino acid basic helix-loop-helix-leucine zipper (bHLHZ) region at its carboxy 
terminus. The bHLHZ specifies dimerization with another bHLHZ protein, Max, which 
is required to activate transcription. Myc-Max heterodimers recognise and bind to DNA 
at E-box elements (CACGTG) via interactions between the basic regions of the bHLHZs 
and the major groove in the DNA, activating transcription at promoters containing these 
elements [41]. Myc-Max dimers can also act as repressors of Myc-regulated genes 
through indirect recruitment to DNA via the zinc-finger protein Miz-1 [30]. Another class 
of bHLHZ proteins including Mad1 (Mad) are also able to heterodimerize with Max and 
bind to E-box elements. The Mad-Max heterodimer works in opposition to Myc-Max and 
acts as a transcriptional repressor, inhibiting cell growth and decreasing cellular 
proliferation [42]. It appears that the fate of a cell to proliferate/transform or 
differentiate/become quiescent is affected by competition between Myc-Max and Mad-















Figure 1: Structure of Myc-Max heterodimer 
bound to DNA [41]. 
 
2.2.3 Regulation of Myc  
Although regulated at several levels, primarily regulation of Myc is at the level of 
transcription in response to growth factor signalling [43]. EGFR is involved in this 
regulation via activation of pathways which drive cellular proliferation (ERK pathway) 
and provide protection from Myc-mediated apoptosis (PI3K-Akt pathway) [44, 45]. 
Overexpression of EGFR is common in TNBC, with 84% of basal-like tumours 
exhibiting this feature [46]. The EGFR signal cascade is implicated in cellular 
proliferation, angiogenesis, metastatic spread and the inhibition of apoptosis [47]. It is 
estimated that EGFR is likely a substitute for the major proliferation pathways of breast 
cancer induced by activation of HER-2, ER and PR proteins which are not highly 
expressed in TNBC [47]. 
 
Interestingly, breast cancer 1 (BRCA1) is also directly involved in the regulation of Myc 




activity [48]. BRCA1 mutations are common in TNBCs and the clinical and pathologic 
features of basal-like breast cancer overlap with hereditary BRCA1 related breast cancer 
[11]. Mutations in the BRCA1 gene predisposes patients to develop many cancers as 
BRCA1 is involved in multiple cellular processes including DNA repair, cell cycle 
control, apoptosis and transcriptional regulation [49]. It is not surprising then that Myc 
amplification is a frequent event in tumours with BRCA1 inactivation [50].  
 
Myc is also regulated at several other levels. The export of the Myc RNA into the 
cytoplasm and its subsequent translation are tightly controlled. Post-translational 
modifications and interactions with other proteins also control Myc’s activity [17]. 
Furthermore, the effects of Myc can be finely tuned to the state of the cell. For example, 
it preferentially binds chromatin in certain states and can preferentially associate with E-
boxes containing epigenetically inherited markers [51]. Every population of cancer cells 
could therefore potentially have different epigenetic patterns that dictate Myc’s binding. 
As Myc transactivation is explored, new levels of complexity continue to make resolving 
Myc’s function a challenge. Although it influences a large number of target genes, its 
effect on any given gene remains weak with the expression of the  majority of target genes 
being amplified only two-fold [52]. 
 
2.2.4 Deregulation of Myc in Cancer  
Increased expression of Myc is thought to occur in an average of 50% of human cancers 
[17]. It is seen in a diverse range of tumour types including a significant proportion of 
lymphoma, melanoma, multiple myelomas, neuroblastoma, ovarian, prostate as well as 
colon, lung and breast cancers [53]. Furthermore, Myc has been shown to be a non-




Myc in a reversibly switchable transgenic mouse model have demonstrated that sustained 
Myc activity is required for tumour maintenance [54]. 
 
Several mechanisms may lead to increased expression of Myc. Unlike other oncoproteins 
such as Ras, there need not be any changes to the coding sequence of Myc for it to unleash 
its oncogenic potential. In most Myc-driven cancers it is a change to another locus (such 
as BRCA1) that causes a downstream effect able to disturb critical regulatory mechanisms 
of Myc, leading to Myc overexpression, enhanced translation or increased protein stability 
[16, 55].  
 
The levels of Myc present in the cell govern how it interacts with the genome. In cells 
expressing high levels of Myc, it can accumulate at the promoter region of active genes 
leading to transcriptional amplification and a decoupling of cellular proliferation from 
growth-factor stimulation. This uncontrolled cellular proliferation can result in genomic 
instability, escape from immune surveillance and immortalization [56]. 
 





Myc’s involvement in tumorigenesis also occurs via several other mechanisms. 
Telomerase, a protein involved in maintaining telomere length, is directly activated by 
Myc through induced expression of its catalytic subunit, telomerase reverse transcriptase 
(TERT). Constitutive expression of Myc and TERT can induce cell immortalisation [57]. 
Myc is also essential for angiogenesis during tumour development and progression and 
is involved in controlling vascular endothelial growth factor expression levels [58]. Myc’s  
reach in cancer development also extends to metastasis through activation of miR-9, a 
negative regulator of the metastasis suppressor E-cadherin, leading to increased cellular 
motility and invasiveness [59].  
 
2.3  Strategies for Myc Inhibition  
Myc’s activation in a wide variety of cancers and its involvement in proliferation and 
apoptosis have made it an attractive target for potential new cancer therapies. 
Transcription factors have traditionally been thought to be undruggable due to their lack 
of enzymatic activity and typical topography, which is large and devoid of features such 
as small molecule binding sites. Recently however, strategies have been devised that 
target Myc at all levels. This includes those aimed at inhibiting Myc’s transcription or 
translation, disrupting Myc/Max dimerization, blocking Myc’s interactions with co-
factors, interfering with the Myc/Max homodimer interaction with DNA, inhibiting 
expression of Myc target genes and promoting Myc protein degradation in the cell [53]. 
These strategies usually involve the use of small interfering RNA (siRNA), antisense 





2.3.1 siRNA  
siRNA is able to induce enzymatic degradation of any mRNA complementary to it 
through interactions with the RNA-induced silencing complex (RISC) [60]. This has been 
utilised to target Myc mRNA sequences with some success. For example, siRNA 
expressed from a plasmid vector has successfully targeted Myc mRNA, reducing Myc 
expression and suppressing breast tumour growth in mice [61]. However, there have been 
several impediments to this approach preventing the translation into new therapies. The 
main obstacle to the use of siRNA as a therapeutic is rapid siRNA degradation in the 
bloodstream by nucleases, resulting in a half-life of only a few minutes [62]. When siRNA 
is delivered systemically, uptake into target organs and cells is generally poor [63]. There 
has been more success with siRNA when delivered locally in non-cancerous disease 
models into tissues such as the eye or lung [64, 65]. The ability to overcome this problem 
through chemical modifications is restricted as limited modifications can be introduced 
for the molecule to remain functional within the RISC [66]. Efficient delivery of siRNA 
remains the most challenging hurdle in the development of siRNA as a therapeutic 
platform. Strategies under investigation to overcome this include creating siRNA 
conjugates, antibody complexed siRNAs and the use of liposomes and lipoplexes [60]. 
There have been other challenges to the therapeutic use of siRNA which have hampered 
progress. These include its ability to activate the innate immune system in mammals and 
issues with off-target effects which have been shown to vary depending on the 
transfection method and the mRNA expression profile of the target cell [67, 68]. 
 
2.3.2 Antisense Oligonucleotides 
Another approach to inhibiting Myc has been antisense oligonucleotides. These are 




mRNA. This also results in the degradation of the target mRNA, although this time 
through recruitment of Ribonuclease H (RNase H). Chemical modifications do not seem 
to affect RNase H activity as readily as seen with the RISC. A typical antisense 
oligonucleotide drug therefore includes a phosphorothioate backbone that links the 
nucleosides and modified nucleotides at each flank to protect it from exonucleases and 
increase stability in vivo [69]. Antisense oligonucleotides have been used successfully to 
reduce Myc expression and cellular proliferation of breast cancer cell lines and in animal 
models of Burkitt's lymphoma, although these have not yet translated into new therapies 
[70, 71]. One problem slowing the development of phosphorothioate antisense 
oligonucleotide drugs has been that some sequences allow interactions with Toll-like 
receptors, inducing a strong immunostimulatory response [72]. The backbone has also 
imparted a toxicity profile that varies with different sequences and can lead to increased 
coagulation time, pro-inflammatory effects and renal tubule changes [69]. Attempts have 
been made to bring antisense oligonucleotide based cancer drugs to market. For example, 
Oblimersen, which targets the mRNA of the gene encoding B-cell lymphoma 2, has been 
tested in over 40 clinical trials since 1999 but the Oblimersen programme was terminated 
after reports of only modest effects, no effects, or missing the expected primary targets 
[73]. Other oligo-based approaches to Myc inhibition under investigation include the use 
of triple helix and tetraplex forming oligos to inhibit Myc mRNA expression, and 
phosphorodiamidate morpholino oligomers to attack translation by preventing ribosomal 
assembly [74-76]. 
 
2.3.3 Small Molecules 
The use of small molecules to target transcription factors is also under investigation. 




Daltons. Inhibition can be aimed at several levels including blocking transcription or 
translation, promoting protein degradation, interfering with interactions with co-factors 
or indirectly inhibiting the function of key target genes [53]. The primary strategy in the 
case of Myc has been to disrupt the protein-protein interaction of the Myc-Max dimer. 
The selective disruption of protein-protein interactions by small molecules has been a 
long sought after goal. There are however a number of factors that have hampered the 
successful development of interfering small molecules. Unlike enzyme inhibitors, which 
compete with natural substrates for small pockets shielded from the aqueous environment, 
protein-protein interaction inhibitors aim to disrupt interactions that occur over large 
surfaces. These surfaces are associated with high free energies of association and are 
generally devoid of regions that readily accommodate small molecules [77]. Small 
molecules able to inhibit heterodimerization of Myc and Max were traditionally identified 
via the screening of large peptidomimetic libraries [78-80]. Yin et al. utilised a yeast two-
hybrid-based assay to screen large numbers of small molecules and identified compounds 
10058-F4 and 10074-G5, which showed specificity for disrupting the interaction of the 
Myc-Max heterodimer [81]. Further development of these two molecules led to studies 
in mice. However, a lack of antitumour activity was seen due to rapid metabolism of these 
molecules [82, 83]. Direct small molecule inhibitors of Myc have had limited success in 
vivo to date due to short half-lives, rapid metabolism, efflux from target cells or inefficient 
tumour penetration [83, 84]. Work is continuing to improve their in vivo stability. 
 
2.3.4 Proteins 
An alternative strategy to inhibit Myc-Max dimerization is the use of a protein rather than 
an oligo-based or small molecule approach. There are several advantages to using a 




greater efficacy, selectivity and specificity than small organic molecules [85]. Another 
advantage is the typically low toxicity profile of protein-based drugs. This is partly 
because the degradation products of proteins are amino acids, minimising the risks of 
systemic toxicity [86]. 
 
Proteins have traditionally been thought of as poor drug candidates. This is usually for 
reasons involving in vitro and in vivo instability or issues related to poor cellular 
penetration or delivery. Protein drugs generally have a low oral bioavailability due to their 
rapid degradation by the proteases in the digestive system, usually requiring injection. 
Bioavailability may also be reduced by their susceptibility to proteolytic degradation and 
hydrolysis in plasma or hepatic or renal clearance [87]. Issues with low permeability 
across biological membranes also need to be overcome. External factors such as 
temperature, pH, contaminants or impurities can compromise the chemical and physical 
stability of a protein. A thorough understanding of their biological and physiochemical 
characteristics is therefore required to ensure the efficacy and safety of any protein based 
drug [88]. 
 
In recent years, however, the interest in protein-based drugs has increased. The global 
market for therapeutic proteins has been growing at a moderate rate and is forecast to 
reach $141.5 billion in 2017 [89]. Several strategies have been devised to overcome the 
issues with stability and delivery. For example, proteins can be chemically modified by 
altering one or more amino acids to create a protein analogue with optimised 
pharmacokinetic properties. This strategy was successful in the development of a 
monomeric rapidly acting insulin analogue [90]. Other methods involve acylation to 




improve receptor-mediated uptake [91, 92]. The advantages and disadvantages of each of 
the strategies for Myc inhibition are summarised in Table 1. 
 
Table 1: Advantages and disadvantages of the main strategies for Myc inhibition 
Strategy Advantages Disadvantages References 
siRNA High specificity 
 
Poor stability in plasma 
Poor intracellular uptake 









Poor intracellular uptake 
Chemistry dependent toxicities 
 
[69, 72] 
Small molecules Greater bioavailability 




Efflux from target cells 
Inefficient tumour penetration 
 
[82-84] 
Proteins/Peptides High affinity to target 
High selectivity and 
specificity 
Low toxicity 
Low oral bioavailability 
Proteolytic degradation  
Low permeability 
Sensitive to external factors 
 
[85, 87, 88] 
 
Improvements have also been made in protein drug delivery with various nanoparticulate, 
protein and peptide delivery systems being developed [93]. These improvements make 
protein-based drugs an attractive option especially in situations where small molecules 
may not be suitable, such as the targeting of transcription factors. 
 
2.4 Omomyc  
2.4.1 What is Omomyc? 
Omomyc is a 92 amino acid protein able to specifically inhibit the dimerization of Myc 
and Max. Omomyc was constructed by Soucek et al. who utilised the fact that Myc is 
unable to form homodimers at physiological concentrations [6]. Four charged amino acids 
two glutamates (E57, E64) and two arginines (R70, R71), located in the leucine zipper 




forming. Omomyc’s sequence was taken from the bHLHZ domain of Myc with the 
critical amino acids preventing dimerization substituted. This altered the dimerization 
specificity of Omomyc allowing it to homodimerize as well as form heterodimers with 
wild-type Myc and Max. The first glutamate was substituted with threonine and the other 
changes mimicked the corresponding amino acids in the Max protein. In the-Max 
homodimer, glutamine and asparagine residues at positions 70 and 71 of the two 
monomers form a remarkably stable tetrad (QN/QN) of major importance for structure 
stabilisation. Poor Myc homodimerization arises due to the disruption of this tetrad, since 
positions 70 and 71 in Myc are occupied by amino acids with the same polarity. The 
presence of three charged residues (the two glutamate 57, 64 and arginine 71) at three 
consecutive positions also destabilise the zipper region [6]. Amino acid sequences can be 
seen in Table 2. 
 
Table 2: Partial Amino Acid sequences of Myc, Max and Omomyc (numbers refer to amino acid 
position in Omomyc) 
 
 
Omomyc can suppress the transcription of Myc target genes via several mechanisms. 
Firstly, by sequestering Myc in the Omomyc-Myc heterodimers, which are incapable of 
binding to E-boxes, less Myc is then available to form the active Myc-Max heterodimers. 
Secondly, by forming Omomyc-Max heterodimers, which can bind to E-box elements 
and act as a competitive inhibitor of the Myc-Max dimer for these sites. Omomyc is also 
able to form stable homodimers which also compete with Myc-Max dimers for DNA 
binding sites [94]. Whilst Omomyc is capable of inhibiting transcriptional activation by 
Myc, it has been found to enhance Myc-induced repression and apoptosis [95]. This is 
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because unlike transactivation, repression by Myc is not dependent on interactions with 
E-box elements but rather with proteins such as Miz1, which is able to interact with 
Omomyc and other DNA elements [96]. Omomyc does not, therefore, cause a global 
inhibition of Myc function, but rather channels its activity towards transrepression; a 
feature which may contribute to its success as an anti-cancer agent. Omomyc has been 
used successfully in animal models and has been able to eradicate KRAS-driven lung 
cancer, inhibit Myc-induced papillomatosis and been effective against glioma in mice 
[97-99]. 
 
2.4.2 Effects of Omomyc in Normal Cells  
Myc is a factor in the coordination of a diverse range of processes necessary for the 
normal growth and expansion of somatic cells, prompting concerns that Myc inhibition 
may cause serious side effects in normal tissue. As Myc is expressed at low to 
undetectable levels in most tissues and organs due to their quiescent nature, there is 
potentially a relatively large therapeutic window in which to target aberrantly expressed 
Myc in tumour cells. The exception to this would be highly proliferative cellular 
populations such as in the haematopoietic system and gastrointestinal precursor cells. 
Based on this, side effects would be expected to be similar to those following treatment 
with cytotoxic agents that non-specifically target all proliferating cells, such as loss of 
intestinal villus integrity and bone marrow aplasia. The effect of Myc inhibition via 
Omomyc was evaluated in a study on transgenic mice with inducible Omomyc expression 
[9]. After four weeks of Omomyc induced Myc inhibition, the animals showed no 
discernible histological changes in any slowly proliferating tissues or organs including 
the heart, lung or kidney. As expected, tissues that experience rapid cell turnover were 




proliferating cells and thinning. Hair regrowth was inhibited and there was a significant 
decrease in proliferation in the intestinal crypts and attrition of villi in the small intestines. 
Loss of spermatogonia and spermatocytes was also evident. However, after withdrawal 
of the stimulus inducing Omomyc expression, all these effects were reversed within one 
week with no discernible deficits or pathology found in any tissue. This study also 
evaluated the effect of Myc inhibition on the haematopoietic lineages. They reported 
significant inhibition of proliferation in bone marrow and rapid onset of anaemia and 
leucopenia. However, by two weeks of sustained Myc inhibition, blood counts had 
returned close to normal levels. Throughout these tests there were no signs of induced 
apoptosis, aberrant differentiation or loss of tissue integrity and no signs of ill health or 
distress were seen in any of the animals. Omomyc was expressed in all tissues in this 
model. In carrying over to a therapeutic setting, targeting of Omomyc to cancer cells 
could significantly reduce these side effects. This could be achieved via several methods, 
for example, by conjugation to a sequence that targets integrins or receptors 
overexpressed on the cancer cells of interest or through the use of targeted nanoparticles. 
 
2.4.3 Omomyc Delivery  
Omomyc has shown some encouraging results as a potential therapeutic for cancer 
treatment. A challenge to the success of this peptide as a useful anti-cancer agent is how 
it is directed into the cancer cells. Some investigative studies into the potential of 
Omomyc in cancer cell lines thus far have used retroviral vectors to have Omomyc 
produced endogenously [96, 98]. Mouse models have utilised transgenic mice in which 
Omomyc expression can be systemically but reversibly induced by administration of 
doxycycline [97, 99]. Whilst these methods are useful in the lab, alternative approaches 




Adenovirus particles can infect a host cell and release its genetic transcript into the 
nucleus to be transcribed into a protein product. This approach is becoming more popular 
in gene therapy research. Adenovirus vectors have been used to mediate expression of 
Omomyc in lung cancer cells [100]. Although anticancer activity has been established via 
the use of adenoviral vectors in preclinical studies, subclinical use of therapeutic 
adenoviral vectors has been limited due to several obstacles including clearance by the 
immune system and limitations in tumour cell delivery [101]. There is thus a need to 
investigate alternative strategies to deliver Omomyc and other anticancer therapeutics to 
cancer cells. 
 
2.5 Cell Penetrating Peptides for the Delivery of Omomyc 
2.5.1 What are Cell Penetrating Peptides? 
The acceleration in the production of large therapeutic molecules in recent years has 
increased the demand for new drug delivery systems able to circumvent the issues 
regarding in vivo stability, cellular uptake, and bioavailability that many of these larger 
molecules display. Ideally, these drug delivery systems will be able to deliver their cargo 
efficiently to the target cells at low doses, lack toxicity, display rapid endosomal release 
and facilitate the therapeutic application of the cargo. Several non-viral strategies for drug 
delivery are being investigated including nanoparticles, lipid and peptide-based solutions. 
 
One peptide-based approach that is gaining momentum is the use of cell-penetrating 
peptides. CPPs (also known as protein transduction domains) are a class of peptides able 
to mediate the internalisation of themselves and a non-permeable molecule (usually 
conjugated to the CPP) into a cell. CPPs are generally less than 30 amino acids in length 




Penetratin) were discovered in the late eighties and early nineties. Tat was derived from 
the HIV-1 Trans-Activator of Transcription (Tat) protein after the observation was made 
that this protein was able to enter cells independently and translocate to the nucleus [102, 
103]. Penetratin was developed shortly after and corresponds to a 16 amino acid sequence 
found in a transcription factor, Antennapedia (Antp), in Drosophila melanogaster. It was 
derived after the discovery that this protein could be secreted without a signal peptide and 
that its subsequent uptake by neighbouring cells was receptor-independent [104]. Other 
CPPs have since been developed such as the VP22 peptide from the herpes simplex virus, 
and the chimeric transportan peptide. Tat and Penetratin, however, remain the most 
extensively characterised CPPs. 
 
The interest in CPPs has been primarily due to their low cytotoxicity and their ability to 
deliver a diverse range of cargo into cells. Although they are able to aid in the 
internalisation of various biomolecules including small molecules, oligonucleotides, 
plasmid DNA and even liposomes and nanoparticles, a significant focus has been on 
mediating the delivery of peptides and proteins [105]. CPPs can be classed into two broad 
groups; those that require the cargo to be chemically linked and those able to form stable 
non-covalent complexes with the cargo. They can also be grouped based on how 
amphipathic they are. 
 
Due to technical artifacts, the mechanism of cellular uptake of CPPs remained puzzling 
for a long while. It was eventually discovered and confirmed that uptake of many CPPs 
is mediated by endocytosis [106, 107]. CPPs such as Tat and Penetratin interact with the 
surface of a cell through electrostatic binding with proteoglycans, leading to the 




to trigger an energy-dependent endocytotic process [108]. Micropinocytosis and clathrin- 
and caveolin–dependent endocytosis have also been reported to mediate internalisation 
of CPP’s and these mechanisms may occur simultaneously [105]. The ability of a peptide 
to escape from an endosome is therefore important and can be a rate-limiting step in CPP-
mediated drug delivery. Several other factors may also affect the cellular uptake including 
the secondary structure of a CPP, the nature, type and concentration of its cargo and the 
membrane composition of the target cell [109]. For example, secondary amphipathic 
CPPs such as Penetratin have weak affinity for zwitterionic membranes but can 
accumulate at high concentrations on anionic membranes [109]. Cellular uptake of CPPs 
has also been found to occur independently of endocytosis. This is favoured when the 
concentration at the cell surface is increased and leads to a more cytoplasmic distribution 
of CPPs [110]. Several mechanisms for this translocation have been proposed but direct 
translocation data are scarce, and it remains challenging to predict due to the complex of 
factors at play. 
 
The in vivo potency of CPPs was first demonstrated in 1999 when a tat-β-galactosidase 
fusion protein showed that delivery into almost all tissues was possible following 
intraperitoneal injection in mice [111]. Since then, CPP-based delivery systems have been 
used to deliver peptides and proteins into cells targeting various processes such as 
stimulating cytotoxic immunity and targeting diseases including asthma, ischemia, 
diabetes and cancer. A principal application has been in anti-proliferative treatments for 
cancer, with much success reported. Many of these studies have used Tat or Penetratin 
conjugated to various peptides including those derived from tumour suppressor p53, 
proapoptotic peptides and inhibitors of cyclin-dependent kinases involved in cell cycle 




slow. First generation CPPs often had issues with cell, tissue or organ specificity. 
Research into cell, organ and disease selective strategies is therefore underway. As entry 
to the cell is often mediated through endocytic pathways, endosomal escape is also critical 
for the cargo to exert its effects in the cell. It has been confirmed by fluorescence-based 
methods and through mass spectrometry that in many cases, CPP-cargo conjugates 
remain trapped in the endocytic pathway [116, 117]. Cargo that remains trapped within 
endosomes cannot reach their cytosolic or nuclear targets and will not display any 
biological activity. Furthermore, they may be subject to degradation in late endosomes or 
lysosomes through hydrolases or acidic pH [118]. 
 
2.5.2 Phylomer-1746 
A new class of CPPs has been recently developed by Phylogica Ltd. (a Perth based 
biotechnology company) through the screening of their Phylomer libraries [119]. The 
phylomer libraries contain genome fragments derived from biodiverse bacteria and 
archaea species. When compared with random peptide libraries, sequences derived from 
natural peptides provide more secondary and tertiary configurations that have been 
optimised for biological activity and interaction, making them a useful reservoir for many 
applications [120]. Several CPP phylomers were selected for potent internalisation 
through the plasma and nuclear membranes. A Split–complementation Endosomal 
Escape (SEE) assay was developed and used to visualise cytosolic internalisation of 
CPPs, differentiating internalisation from endosomal entrapment [121]. One phylomer 
which was identified as showing superior internalisation and endosomal escape is a 38 
amino acid sequence, Phylomer-1746 (unpublished). A recombinant fusion protein 
comprising of Phylomer-1746 linked to the Omomyc sequence (1746-Omomyc) was 




basal-like cell lines (unpublished). It is of interest to investigate the mechanisms involved 
and address Myc inhibition in cancer cell lines treated with this protein. 
 
2.6 Recombinant versus Synthetic Production of Therapeutic proteins 
Omomyc and 1746-Omomyc are large molecules, with Omomyc alone comprising 92 
amino acids. The size of a therapeutic protein is important for several reasons. Larger 
molecules usually have lower tissue penetration and may have a lower level of activity 
per unit mass [122]. The key benefit to reducing the size of a therapeutic protein, however, 
is an increase in the technological options available for its manufacture. Generally, 
peptides up to 100 amino acids in length can be produced chemically through solid phase 
peptide synthesis (SPPS). As the length of a peptide increases, the yield of pure peptide 
decrease due to poor coupling efficiencies, making this technology unsuitable for larger 
proteins [123]. There are several potential benefits of utilising SPPS compared with 
recombinant expression. Recent developments have allowed large-scale chemical 
synthesis of small and medium sized peptides to become a viable option with reduced 
manufacturing costs [124]. Recombinant production can be expensive as it involves 
complex manufacturing processes and the development of stable cell lines. Chemical 
synthesis also allows for greater chemical diversity. For example, unnatural and D-amino 
acid substitutions can be made and may provide benefits such as greater stability in 
plasma [125]. There can also be benefits in terms of product purity. The quality and purity 
of recombinant molecules are not always optimal. Chemical synthesis allows the product 
to be easily separated from impurities and side products and also provides a reduced risk 





Although Omomyc is large, the amino acid substitutions allowing for its interaction with 
Myc all occur within a small 15 amino acid region. It is therefore of interest to determine 
if a truncated version of Omomyc (Omi), a 28 amino acid peptide derived from the 
interference region of Omomyc, would also show sufficient activity in inhibiting Myc 









































3. Hypotheses and Aims 
Hypotheses:  
That interference peptides 1746-Omomyc, 1746-Omi and Penetratin-Omi will inhibit 
Myc in TNBC cell lines leading to reduced proliferation and/or cancer cell death. 
 
Aims:  
1. To investigate the level of Myc expression in a panel of tumorigenic and non-
tumorigenic human and murine mammary cell lines using qRT-PCR. The murine 
panel includes one non-tumorigenic (NIH-3T3), and three triple-negative cell 
lines (T11, A1.8, B.15). The human panel includes one non-tumorigenic (HDEF), 
three triple negative (SUM149, SUM159, MDA-MB-231) and two hormone 
receptor positive (MCF7 and ZR-75-1) breast cancer cell lines. 
2. To determine the IC50 of interference peptide 1746-Omomyc in the same panel of 
cell lines and investigate whether the response is Myc or tumour subtype 
dependent. 
3.  To determine the half maximal inhibitory concentration (IC50) of the truncated 
peptide (Omi) conjugated to both a traditional CPP, Penetratin (Penetratin-Omi) 
and phylomer-1746 (1746-Omi) in T11 cells. 
4. To investigate the mechanisms of inhibition of the three peptides using a Ki-67 
Proliferation Assay and an Annexin V and Propidium Iodide staining kit. 
5. To investigate Myc inhibition by evaluating the expression of known downstream 





4. Materials and Methods 
4.1 Cell lines 
The NIH-3T3, MCF7, ZR-75-1, HDEF and MDA-MB-231 cell lines were acquired from 
ATCC. SUM159 and SUM149 cell lines were obtained from Asterand Bioscience. The 
T11, A1.8 and B.15 lines were gifted from collaborators.  T11, A1.8 and B.15 cells were 
grown in RPMI-1640 media with 10% Foetal Bovine Serum (FBS). NIH-3T3, HDEF and 
MDA-MB-231 cells were grown in DMEM with 10% FBS. SUM159 cells were grown 
in Hams F-12 media with 5% FBS, 1 µg/ml of hydrocortisone and 1.25 µg/ml insulin. 
SUM149 cells were grown in Hams F-12 media with 10% FBS. MCF7 cells were grown 
in EMEM with 10% FBS and 1% each of sodium pyruvate, sodium bicarbonate and non-
essential amino acids. ZR751 were grown in RPMI-1640 with 10% FBS, 2 mM glutamine 
and 1mM Sodium Pyruvate. All media had 1% Antibiotic-Antimycotic added. 
 
4.2 Peptides 
1746-Omi, Penetratin-Omi, Omi, Penetratin, FITC-1746 and the Mutant Penetratin-Omi 
were synthesised by China Peptides Co., Ltd, Shanghai, China using SPPS. The peptides 
came in the form of a lyophilized powder. Each peptide came with a High-Performance 
Liquid Chromatography report indicating the product purity and a Mass Spectral Analysis 
report. All peptides had a high purity grade of above 95% making them suitable for 
quantitative as well as qualitative studies. Peptides were stored at -20°C. At first use 
peptides were diluted in phosphate-buffered saline (PBS) and frozen at -20°C in small 
aliquots for use in experiments. 1746-Omomyc, Omomyc and 1746 were supplied by 





4.3 Quantifying Myc mRNA expression in mouse and human cell line panels 
4.3.1 RNA extraction and quantification 
All cell lines wells were grown on 10cm tissue culture plates until they were 
approximately 90% confluent in the appropriate media. Cells were washed with PBS 
before trypsin was added to detatch cells from the plate. Trypsin was inactivated by 
adding media and cells were centrifuged to produce a pellet. Pellets were washed twice 
with PBS. Cells were resuspended in 600µL of Trizol and frozen at -80°C until needed. 
All samples were defrosted in their tubes on ice. 120µL of chloroform was added and 
tubes were vortexed at high speed for 15 seconds. Samples were incubated on ice for 3 
minutes and centrifuged (4°C, 12,000 rpm, 20 minutes) to separate.  The supernatant 
containing the RNA was transferred to a new Eppendorf tube. 300µL of cold (-20°C) 
isopropanol was added and samples were vortexed lightly. Samples were incubated on 
ice for 10 minutes and then stored at -20°C for 1 hour. Samples were then centrifuged 
(4°C, 13,000 rpm, 40 minutes). Supernatant was discarded and pellets were washed twice 
with 75% ethanol by adding ethanol to tubes, centrifuging for 10 minutes at 4°C and 
discarding the ethanol. Pellets were air dried at room temperature before being 
resuspended in 40µL nuclease free water and incubated at 4°C for 1 hour. The 
concentration of RNA in each sample was quantified using a NanoDrop 
spectrophotometer which calculates the concentration based on the light absorbance at 
260 nm. All samples showed 260nm/280nm absorbance ratios above 1.8 and 
260nm/230nm absorbance ratios above 2.2 indicating the samples were free of protein, 





4.3.2 cDNA synthesis and qRT-PCR 
The RNA samples were converted to complementary DNA (cDNA) using a High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) with the amount 
of RNA added calculated to give each sample an equal final RNA concentration. cDNA 
was synthesised using the BioRad S1000 Thermal Cycler. Samples were stored at -20°C 
until needed. qRT-PCR was performed using TaqMan Fast Universal Master Mix and the 
ViiA 7 Real-Time PCR system (Applied Biosystems). Each sample was run in triplicate 
with both human and mouse Myc and GAPDH TaqmanR probes. Non-template controls 
were included for each probe. 
 
4.3.3 Analysis of data using the Delta Delta CT method 
The amplification plots were checked to ensure that triplicates for each sample had 
minimal variation. The amplification plots of the controls were checked and there was no 
evidence of contamination. A Ct value was obtained for each sample and the analysis was 
calculated manually using Excel. The mean Ct value and standard error for each sample 
were calculated from the triplicate data. The error was calculated from the standard error 
values for Myc and GAPDH for each cell line. The Delta Ct Standard Errors were 
calculated using the NIH-3T3 cell line as the control for the mouse panel and the HDEF 
line as the control for the human panel. Delta Ct was calculated for GAPDH and Myc by 
subtracting the mean sample Ct value from the mean control (NIH-3T3 or HDEF) Ct 
value. Double Delta Ct was calculated by subtracting the Delta Ct from the housekeeping 
gene (GAPDH) from the Delta Ct of our gene of interest (Myc). The ratio of expression 





4.4 Cell Viability Assays 
4.4.1 Peptide Treatment and CellTiter-Glo 2.0® Assay 
In each experiment, cells were plated in 96 well plates at 3000 cells per well and incubated 
in 5% CO2 at 37°C for 24 hours before treatment. The calculated amount of peptide for 
each concentration was added to media in tubes and lightly vortexed. Media was then 
aspirated from the wells and 100µL of the media-peptide mix added to each well. 
Triplicate wells of cells were treated with each concentration of peptide tested. A control 
well with no cells was also treated for each concentration to act as a background for the 
luminescence when the assay was read. Plates were read after 24 hours incubation using 
a CellTiter-Glo® 2.0 Assay from Promega. The reagent was added, plates shaken for 2 
minutes then the luminescence measured using the Wallac Envision™ 2102 Multilabel 
Reader after 10 minutes. This assay indicates the number of viable cells by quantitating 
the amount of ATP present. Each experiment was repeated three times, although in some 
cases only two repeats were carried out due to limitations on time and resources. 
 
4.4.2 Calculating IC50 values 
Readouts from the CellTiter-Glo 2.0 Assay were first processed using excel to get an 
average value for each well over the eight iterations read and then the average value for 
each concentration tested. The background value recorded for the treatment wells 
containing no cells was then subtracted. The luminescence value for the control wells 
with no peptides added was taken to indicate 100% viability and the rest of the data 
compared to this value to give the percentage of viable cells under each concentration of 
peptide tested. The graphs and IC50 values were produced using GraphPad Prism 7. The 
concentrations were transformed using a Log conversion and a sigmoidal standard curve 




4.4.3 Statistical Analysis 
All p-values comparing treatments were based on independent sample t-tests calculated 
using SPSS. The relationship between Myc level and response to 1746-Omomyc were 
analysed using linear regression in SPSS. A Log transformation of the response to 1746-
Omomyc was used for the human panel. Q-Q plots of observed versus expected values 
indicated the assumption of normally distributed data was upheld. The assumption of 
homeoscadacity was checked by looking at residuals versus predicted values and did 
include some deviations. 
 
4.5 Ki-67 Proliferation Assays 
4.5.1 Treatment procedure and conditions for Ki-67 Assay 
Cells were seeded at 3,000 cells per well in transparent 96 well plates and incubated in 
5% CO2 at 37°C for 24 hours before being treated. A second white bottomed control plate 
was also seeded with cells. Four wells of cells were treated with each peptide being tested 
at 2.5µM for 1746-Omomyc, 25µM for Penetratin-Omi and the mutant Penetratin-Omi 
and 9µM for the positive control (SV40-EN1 ipep) as well as four control wells with no 
treatment. Triplicate wells on the control plate were also subjected to each treatment. 
Cells were incubated for 24 hours. Cell viability was tested on the control plate using a 
CellTiter-Glo 2.0 Assay to ensure all peptides were active and the test plate was fixed and 
stained. 
 
4.5.2 Immunofluorescence staining  
Media was aspirated and the cells fixed with 4% Formaldehyde in PBS. Cells were 
washed in PBS and permeabilised with 0.5% Triton™ X-100 in PBS for 15 minutes at 




Bovine Serum Albumin (BSA) in PBS. Blocking solution was aspirated and the cells 
treated with a 1:400 dilution of a Ki-67 Mouse monoclonal antibody (mAb) purchased 
from Cell Signalling Technology® diluted in 1% BSA in PBS. The fourth well for each 
treatment had only 1% BSA in PBS added with no primary Ki-67 antibody to act as a 
control. Cells were incubated on a shaker at 4°C overnight. Cells were washed three times 
with 0.1% Tween 20 in 1% BSA in PBS and a Goat anti-Mouse IgG secondary antibody, 
Alexa Flour® 488 conjugate was added in a 1:1000 dilution. The plate was wrapped in 
foil and incubated at room temperature on a shaker for 1 hour. Cells were washed three 
times with washing solution and then stained with a Hoechst nuclear stain. Cells were 
washed three times in washing solution and two times in PBS and were stored at 4°C 
covered in PBS and wrapped in foil until reading. 
 
4.5.3 Imaging and Data Analysis 
Images were captured using the Olympus IX71 Inverted Fluorescence Microscope and 
AnalySIS image capture software. Images used for quantification were at 10x 
magnification with the exposure set manually and kept constant across all images. Images 
of three fields of view were taken for each well. The total number of cells for each field 
of view was counted manually from the image with the Hoechst filter using the ImageJ 
cell counter plugin. The number of Ki-67 positive cells was determined by counting the 
number of fluorescent cells obviously visible in the corresponding image using the green 
filter image with the brightness and contrast kept constant for all images counted. 
Statistics and graphs were produced using GraphPad Prism 7. The mean and standard 






4.6 Annexin V and Propidium Iodide Assay 
4.6.1 Peptide treatments and procedure for Annexin V and PI Assay 
T11 cells were plated in 6 well plates at ~90000 cells per well (scaled up from the 3,000 
cells per well used in previous experiments on 96 well plates) and incubated for 24 hours 
before being treated. One well was treated with each of the following: 1746-Omomyc, 
Omomyc and 1746 at 2.5µM, Penetratin-Omi, Mut Penetratin-Omi and Penetratin at 
25µM and a control well with no peptide added.  Triplicate wells of T11 cells in a separate 
96 well plate were also treated at the same time with the same preparation of peptides to 
act as a control on the level of cell viability under each treatment. After 24 hours 
incubation, cell viability was measured in the control plate using a CellTiter-Glo 2.0 
Assay and an Invitrogen™ Dead Cell/ Apoptosis Kit was used to quantify the number of 
living, dead and early apoptotic cells in the treated cells in the 6 well plates. The 
supernatant was collected for each sample. Adherent cells were removed using trypsin, 
added to the supernatant and centrifuged. Supernatant was discarded and cells washed in 
cold PBS. Each sample of cells was resuspended in 100µL Annexin binding buffer. 5 µL 
of the FITC-Annexin V and 1µL of a 100µg/ml Propidium Iodide solution were added to 
each sample and incubated at room temperature for 15 minutes. A further 400µL of 
Annexin binding buffer was added and samples kept on ice until reading. Cells were 
counted using the BD FACS Aria II Special Order System, USA. FITC was detected with 
the blue laser at 488nm and Propidium Iodide with the Yellow/Green laser at 552nm with 
acquisition criteria of 100,000 events per tube. Single cells were gated into four 





4.7 mRNA expression of downstream Myc targets 
4.7.1 Treatment procedure and conditions  
T11 cells were seeded onto a 6 well plate at ~90000 cells per well and incubated at 37°C 
for 24 hours. One well of each plate was treated with 1746-Omomyc, 1746 and Omomyc 
at 5 µM, Penetratin-Omi and Mut Penetratin-Omi at 50µM and a control well with no 
peptide added. The cells were collected after 3 hours by aspirating media and 
resuspending in 400µL trisol. Samples were frozen at -80°C. RNA was extracted and 
quantified using the same method as above for the Myc mRNA quantifications. 
 
4.7.2 qRT-PCR and data analysis 
cDNA was synthesised and qRT-PCR carried out as described in 4.3.2. Triplicate wells 
were run for each of the samples with each of the probes: MYC, CCND1, MINA, E2F2, 
CDKN1A and GAPDH (Taqman®). Non-template control wells for each probe were 
included. The data was analysed using the Delta Delta Ct method as described in 4.3.3 









5.1 Myc mRNA expression in cell line Panels 
5.1.1 Description of cell lines 
To identify the most suitable cell lines to use in experiments aimed at inhibiting Myc and 
determine if Myc levels are predictive of a response to the 1746-Omomyc peptide, Myc 
mRNA levels were quantified in a panel of murine (NIH-3T3, T11, A1.8, B.15) and 
human (HDEF, SUM149, SUM159, ZR-75-1, MCF7, MDA-MB-231) cell lines using 
qRT-PCR. 
 
The NIH-3T3 cell line is a non-tumorigenic line of immortalised mouse embryonic 
fibroblasts and was used as a non-tumorigenic reference/control in the mouse panel. The 
other three murine cell lines tested are tumorigenic. The T11 cell line is a p53 null, mouse 
mammary tumour model [126, 127]. It is characteristic of the claudin-low subtype and is 
negative for ER, PR and HER-2 overexpression. Both the A1.8 and B.15 cell lines were 
generated from BRCA1 deficient mouse mammary tumours [128]. They are both of the 
basal subtype and also display a triple-negative phenotype. 
 
HDEF cells are a non-tumorigenic cell line derived from normal adult human dermal 
fibroblasts and were used as a reference/control to quantify Myc levels in the human 
panel. SUM149 and SUM159 are both p53 deficient tumorigenic human cell lines of the 
triple-negative phenotype. SUM149 cells have been characterised as basal-like whilst 
SUM159 cells are characteristic of the claudin-low subtype displaying high enrichment 
for epithelial-to-mesenchymal transition markers, immune response genes and cancer 
stem cell-like features [19]. MDA-MB-231 is also a tumorigenic human cell line with a 




basal subtype, however, they have also been shown to display characteristics consistent 
with claudin-low tumours [19]. ZR-75-1 and MCF7 are both hormone receptor positive 
tumorigenic human breast cancer cell lines of the luminal subtype. The characteristics of 
the cell lines used are summarised in Table 3. 
 
Table 3: Cell lines tested and their characteristics. 
Cell line Origin BC Subtype Description 
NIH-3T3 Mouse N/A Murine Embryonic Fibroblasts 
T11 Mouse Claudin-low P53mut, TN 
A1.8 Mouse Basal-like BRCA1- , TN 
B.15 Mouse Basal-like BRCA1- , TN 
HDEF Human N/A Human Dermal Fibroblast 
SUM159 Human Claudin-low P53mut, TN 
MDA-MB-231 Human Claudin-low P53mut, TN 
SUM149 Human Basal-like P53mut, TN 
MCF7 Human Luminal ER+, PR+ 
ZR751 Human Luminal ER+ 
 
5.1.2 Highest Myc expression in the triple-negative breast cancer claudin-low cell 
lines 
In both the murine and human panel of cell lines, the highest Myc expression was seen in 
the claudin-low subtype. In the murine panel, Myc mRNA levels were elevated in all three 
of the tumorigenic cell lines tested when compared to the non-tumorigenic NIH-3T3 cells 
(Figure 3A). The T11 cells (claudin–low) had the highest level with a 1.35 fold expression 
of Myc compared with the control. The two basal-like cell lines showed similar expression 
levels with a 1.28 fold increase for A1.8 and a 1.22 fold increase for B.15 cells. 
 
Myc mRNA levels in the human panel were normalised to levels in the non-tumorigenic 




(Figure 3B). The luminal ZR-75-1 cells showed the smallest increase of 1.33 fold. The 
luminal MCF7 cells and basal-like SUM149 cells expressed similar levels of Myc at 4.96 
and 4.71 fold increased expression. The highest Myc expression was seen in the claudin-




5.2. 1746-Omomyc Dose Responses in panels of cell lines 
5.2.1 Greatest response to 1746-Omomyc in triple-negative claudin-low cell lines 
The 1746-Omomyc peptide was delivered in a range of doses to both the murine and 
human panels of cell lines. The percentage of viable cells after 24 hours treatment was 
quantified against untreated controls using a CellTiter-Glo cell viability Assay. In the 
murine panel, the largest decrease in the number of viable cells was seen in the claudin-
low T11 cells with an IC50 value of 2.123µM (95% CI 1.833 to 2.46) (Figure 4A). The 
basal-like B.15 were also responsive to the peptide with an IC50 of 2.298µM (95% CI 
1.998 to 2.644). A1.8 cells were affected to a lesser extent at lower concentrations but 
substantially at the highest concentration. NIH-3T3 cells were far less responsive. At the 
Figure 3: Myc mRNA levels are highest in the claudin-low cell lines. A. c-Myc mRNA levels 
determined by qRT-PCR in a murine panel of cell lines. Calculated using the Delta Delta Ct method 
with GAPDH as the reference gene and normalised to expression levels in NIH-3T3 cells. B. c-Myc 
mRNA levels determined by qRT-PCR in a human panel of cell lines. Calculated using the Delta 
Delta Ct method with GAPDH as the reference gene and normalised to HDEF c-Myc expression 






maximum concentration tested of 15µM, the percentage of viable NIH-3T3 cells was 
reduced to a mean of 42.43% of that seen in non-treated controls. In all three tumorigenic 
cell lines tested the mean percentage of viable cells at this concentration was much 
smaller at 2.15% in T11, 6.85% in B.15 and 5.44% in A1.18 cells. 
 
In the human panel, the greatest response to the 1746-Omomyc peptide was also seen in 
a claudin-low cell line, SUM159, which had an IC50 of 2.177µM (95% CI 1.85 to 2.563). 
(Figure 4B). The basal-like SUM149 were also substantially affected with an IC50 of 
3.417µM (95% CI 2.847 to 4.1). In contrast, the non-tumorigenic HDEF cells were not 
affected as greatly by the peptide with the number of viable cells measured at 84.71 
percent of that seen in the non-treated control cells at the maximum concentration tested 
of 15 µM. The results were similar for the luminal MCF7 cells with cell viability 
measured at a mean of 86.84 percent seen in non-treated controls still viable after 24 hours 
treatment at 15µM. Luminal ZR-75-1 cells were not greatly affected with peptide 
concentrations up to 5µM, but cell viability dropped to 41.66 percent of the control at a 
concentration of 15µM. Results were similar in the claudin-low MDA-MB-231 cells 
which showed no response at 2.5µM but was inhibited at concentrations of 5µM and 
15µM. 
 
Dose responses of the 1746 and Omomyc peptides were also tested at a range of 
concentrations up to 15µM in a representative cell line to act as controls. The T11 cell 
line was chosen as it showed the greatest reduction in cell viability when treated with the 
1746-Omomyc peptide. Neither the 1746 or Omomyc peptides produced a decrease in 










5.2.2 Response to 1746-Omomyc correlates with Myc RNA levels in Human Panel 
In both the murine and human panel, the response to 1746-Omomyc was greatest in the 
cell line with the greatest Myc mRNA expression. Linear regression analysis was 
undertaken to determine if there was a significant relationship between Myc RNA levels 
and the response to the 1746-Omomyc peptide. Data from the percentage of viable cells 
at 2.5µM was used as this was the closest data point to the IC50 of the most responsive 
cell lines in both the murine and human panels. In the murine panel, although the cell line 
with the highest Myc levels (T11) had the greatest response, a significant relationship 
Figure 4: Dose response curves of 1746-Omomyc on (A) murine cell line panel and (B) human 
cell line panel. Tested at concentrations ranging from 0.25 to 15µM. Cells were treated for 24 hours 
and cell viability assessed using CellTiter-Glo Assays. The percentages of viable cells were 
normalised to non-treated control cells. Data points are the mean of three independent experiments 
for NIH-3T3, T11, SUM159 cell lines and two experiments for the remaining cell lines. Error bars 
represent SEM. C. Dose response of 1746-Omomyc with 1746 and Omomyc as controls presented 
as mean and SEM of three independent experiments. Where error bars can’t be seen they are 





between response to 1746-Omomyc and Myc level was not found (p = 0.309). This result, 
however, was based on a very small dataset with Myc levels being in a very small range, 
limiting the value of such an analysis. In the human panel, a significant linear relationship 
between Myc RNA level and response to the 1746-Omomyc was found with a lower 
percentage of viable cells compared to the control after treatment in cells with higher Myc 
levels (p = 0.033). 
 
5.3 1746-Omi and Penetratin-Omi Dose Responses 
A truncated 28 amino acid version of the Omomyc peptide was synthesised (Omi) which 
corresponds to amino acids 54 to 81 of the Omomyc peptide (See Table 2). Rather than 
containing the entire basic helix-loop-helix-leucine zipper region of Omomyc, this 
peptide corresponds only to the critical portion of the protein that is involved in 
dimerization [6]. The Omi peptide linked to the CPPs 1746 (1746-Omi) and Penetratin 
(Penetratin-Omi) were produced via SPPS. 
 
5.3.1 CPP-Omi conjugates have increased IC50 values  
Dose-response data were obtained for 1746-Omi, Penetratin-Omi and controls (1746, 
Penetratin, and Omi) in T11 cells treated for 24 hours using a CellTiter-Glo cell viability 
Assay. The IC50 for 1746-Omi was 26.24µM (95% CI 22.38 – 30.76), which was nearly 
10 fold higher than the concentration needed for 50% cell death using the 1746-Omomyc 
peptide (Table 4). Penetratin-Omi produced an IC50 of 20.6 µM (95% CI 16.19 – 26.2). 
When administered alone neither CPP nor Omi caused a reduction in the number of viable 










Mutant Penetratin-Omi 24.95 
 
5.3.2 Greater reduction in cell viability produced by Penetratin-Omi than 1746-Omi 
Penetratin-Omi was found to reduce the number of viable T11 cells significantly more 
than the 1746-Omi peptide at concentrations of 10, 15 and 20µM from a mean of 94.4% 
for 1746-Omi to 83.3% for Penetratin-Omi at 10µM (p = 0.035), from 87.0% to 67.1% at 
15µM (p = 0.026) and from 80.9% to 52.1% at 20µM (p = 0.012) (Figure 5). 
To determine its suitability for internalisation studies, cell viability of T11 cells treated 
with a FITC labelled 1746 peptide was also measured. The number of viable cells was 
reduced greatly to 59.8 ± 4.14% (mean ± SEM) of the control at the maximum 
concentration tested of 50 µM. In comparison, cell viability was 98.8 ± 0.16% (mean ± 




Table 4: Increased IC50 in CPP-Omi conjugates 
Comparison of peptides IC50 in T11 cells 
Figure 5: Greater reduction in cell 
viability for Penetratin-Omi than 
1746-Omi. Dose response data of 
Penetratin-Omi, 1746-Omi, Penetratin, 
1746 and Omi in T11 cells treated at 
concentrations from 0.25 to 50µM for 
24 hours and cell viability assessed 
using CellTiter-Glo Assays. Percentage 
of viable cells was normalised to non-
treated control cells. All data points are 






5.3.3 CPP-Omi conjugates show selectivity towards cancer cell line  
1746-Omi and Penetratin-Omi were also tested in the non-tumorigenic NIH-3T3 cell line. 
In this cell line neither peptide produced any decrease in cell viability even at the highest 
concentration tested of 50µM (Figure 6A, 6B).  
5.3.4 Mutant Penetratin-Omi also reduces cell viability 
Given the greater potency and favourably smaller size of Penetratin-Omi over 1746-Omi 
and the greater characterisation of the penetratin CPP, Penetratin-Omi was chosen for use 
in further experiments. An altered version of the Penetratin-Omi peptide was produced 
via SPPS to act as a control in which the four amino acids critical in dimerization were 
replaced by alanine (Mutant Penetratin-Omi). The altered version of the peptide was also 
found to produce a decrease in cell viability with an IC50 of 24.95µM (95% CI 23.06 – 
26.99) (Figure 7).  The difference in the percentage of viable cells when treated with 
Penetratin-Omi and Mutant Penetratin-Omi was found to be significantly different at 
concentrations of 10, 15 and 20µM (p = 0.025, 0.045 and 0.047 respectively). At 10µM, 
Figure 6: Penetratin-Omi and 1746-Omi show selectivity towards the cancer cell line. A. 
Dose-response data of 1746-Omi in T11 and NIH-3T3. B. Dose-response data of Penetratin-Omi 
in T11 and NIH-3T3. Treated at concentrations from 0.25 to 50µM for 24 hours and cell viability 
assessed via CellTiter-Glo Assays. Percentage of viable cells was normalised to non-treated control 
cells. All data points are presented as mean ± SEM for three independent experiments. Where no 




the mean percentage of viable cells when compared to an untreated control was 83.33% 
for Penetratin-Omi and 93.08% for the Mutant. At 15µM, viability was 67.06% for 
Penetratin-Omi and 83.39% for the Mutant. At 20µM, Penetratin-Omi reduced the 
number of viable cells to 52.07% whilst the Mutant reduced the number to 67.29%. 
 
5.4. Proliferation and Dead Cell/Apoptosis Assays 
The 1746-Omomyc, 1746-Omi, Penetratin-Omi and Mutant Penetratin-Omi peptides all 
produced a reduction in viable cancer cells. The CellTiter-Glo Assay used to measure this 
reduction is based on quantitating the amount of ATP present in a sample, indicating the 
presence of metabolically active cells. This does not inform us of the extent to which the 
reduction in the number of viable cells was produced via reduced proliferation or through 
cell death. To get a clearer idea of the extent to which the reduced cell viability was due 
to a reduction in proliferation or through cell death a Ki-67 Proliferation Assay and an 
Annexin V and Propidium Iodide Dead Cell/Apoptosis Assay were performed. 
 
5.4.1 1746-Omomyc reduces viable cells through reduced proliferation in T11 cells 
Ki-67 is a useful marker of proliferation as it is universally expressed in proliferating cells 
and is detectable in G1, S, G2 and mitosis, but is absent in quiescent cells in the G0 resting 
Figure 7: Mutant Penetratin-Omi also 
reduces cell viability. Dose-response 
data of Penetratin-Omi and Mutant 
Penetratin-Omi in T11 cells. Treated at 
concentrations from 0.25 to 50µM for 24 
hours. Cell viability assessed via 
CellTiter-Glo Assays. Percentage of 
viable cells was normalised to non-
treated control cells. All data points are 
presented as mean ± SEM for three 
independent experiments. Where no 
error bars can be seen they are smaller 




phase [130]. Ki-67 positive cells were quantitated in peptide treated T11 cells using a Ki-
67 antibody and fluorescently labelled secondary antibody. In the control, 89.36 ± 0.657% 
(mean ± SEM) of cells were positive for the Ki-67 protein indicating that they were 
proliferative (Figure 8). This proportion was significantly reduced (p < 0.001) in the cells 
treated with the 1746-Omomyc peptide to 46.87 ± 1.422% (mean ± SEM). In the cells 
treated with the Penetratin-Omi, 76.21 ± 1.414% (mean ± SEM) were still proliferative. 
This was significantly less than seen in the control cells (p < 0.001) but significantly more 
than in cells treated with 1746-Omomyc (p < 0.001). The proportion of proliferative cells 
when treated with Mutant Penetratin-Omi, was not significantly different from what was 
seen in the cells treated with Penetratin-Omi (p = 0.342) with 78.43 ± 1.785% (mean ± 





5.4.2 Penetratin-Omi and Mutant reduce cell viability through cell death in T11 cells  
Annexin V is able to identify early apoptotic cells by binding to phosphatidylserine which 
is translocated from the inner to the outer leaflet of the plasma membrane during the 
























































Figure 8: 1746-Omomyc reduces 
proliferation in T11 cells. T11 cells 
treated for 24 hours at 2.5µM for 1746-
Omomyc and 25µM for Penetratin–Omi 
and Mutant Penetratin-Omi. Data is mean 
number of Ki-67 positive cells over nine 
fields of view at 10x magnification for 
each treatment. Error bars are standard 




impermeant to live and early apoptotic cells, but stains dead or late apoptotic cells with 
red fluorescence. 
 
T11 cells were stained using a FITC-Annexin V and Propidium Iodide staining kit after 
being treated with the peptides and controls for 24 hours at the same concentrations as 
used in the Ki-67 assay. Cells were counted using FACS (Figure 9). In the control, the 
majority of cells (94.7%) were negative for both Annexin V and PI, indicating non-
apoptotic, viable cells. Only 0.2% of cells were Annexin V+, PI- indicating cells in early 
apoptosis. 1.9 % of the control cells stained Annexin V-, PI+ corresponding to dead cells, 
with the remaining 3.2% of cells Annexin V+, PI+. These cells may be in late apoptosis 
or dead. This assay is unable to distinguish between dead cells that have undergone 
apoptotic death versus a necrotic pathway as once membrane integrity is lost necrotic 
cells may also stain positive for Annexin V. All control peptides (Omomyc, 1746 and 
Penetratin) produced results very similar to the untreated control cells (Sup. Figure 2). 
 
After treatment with 1746-Omomyc, the majority of cells were also viable and non-
apoptotic (85.9%). Early apoptotic cells were at the same level seen in the control at 0.2% 
with the remaining 13.9% of cells PI+. The Penetratin-Omi treated cells had a much lower 
proportion of live cells at 37.0%, a higher proportion of early apoptotic cells at 1.3% and 
a large number of PI+ cells at 61.7%. The mutant Penetratin-Omi treated cells had a higher 
proportion of live cells at 77.7%, 2.1% early apoptotic cells and a total of 20.2% PI+ cells. 
  
The proportion of dead cells after treatment with each peptide are not directly comparable 
as the peptides have different IC50 values. A separate plate of cells was treated at the same 





used to determine the number of viable cells after each treatment when compared to a 
control. The data from the two assays is compared in Table 5. The number of viable cells 
compared to a control after 24 hours incubation with 1746-Omomyc at 2.5µM was 
reduced to 38.7%. The proportion of live cells in the corresponding sample assessed via 
FACS,  however, was not greatly reduced with 86.1% of cells still viable (only 8.8% 
lower than the control) with the number of dead cells being very low. This supports the 
result of the Ki-67 proliferation assay which showed a marked reduction in the number 
of proliferating cells following treatment with this peptide. When incubated for 24 hours 
with Penetratin-Omi at 25 µM, the number of viable cells was reduced to 34% of the 
control. Most of this reduction is accounted for by dead cells with the total number of PI-
positive cells counted at 61.7%. This result is also supported by the result of the Ki-67 
proliferation assay which showed only a small reduction in proliferating cells compared 
to the control. In the cells treated with Mutant Penetratin-Omi for 24 hours at 25µM, the 
number of viable cells was reduced to 48.9% of the control based on the CTG assay. The 
Figure 9: Penetratin-Omi and mutant 
reduce cell viability through cell 
death. FACS analysis of T11 cells 
treated for 24 hours with 1746-Omomyc 
at 2.5µM, Penetratin-Omi and mutant 
Penetratin-Omi at 25µM and stained 





proportion of PI-positive cells was lower than expected at 20.2%, however, there was no 
corresponding decrease in the number of proliferating cells as was seen for the 1746-
Omomyc peptide. 
 
Table 5: Comparison of the percentage of viable cells after treatment compared to a control 
versus percentage of viable cells after treatment as a percentage of the sample.  
. 
Treatment IC50 of peptide 
in T11 
Viable cells 





Control  100 94.7 
1746-Omomyc (2.5µM) 2.12 38.7 85.9 
Penetratin-Omi (25µM) 20.60 34.0 37.0 
Mutant Penetratin-Omi (25µM) 24.95 48.9 77.7 
 
Total viable cells: Results of FACS analysis on FITC-Annexin V and PI stained T11 cells treated for 24 hours. Viable 
cells (% of control) based on CellTiter-Glo 2.0 Viability Assay with same treatments on separate plate 
 
 
5.5 qRT-PCR on Downstream Myc targets 
5.5.1 Selection of downstream Myc targets  
To determine if the mechanism of action of the Penetratin-Omi and Mutant Penetratin-
Omi peptides was consistent with Myc inhibition, their effect on known downstream Myc 
targets was investigated. An RNA-Seq analysis of T11 cells treated with 1746-Omomyc 
and controls had previously been carried out (data are still being analysed by 
collaborators). Five genes known to be responsive to Myc protein levels were selected 
that were found to be either up- or down-regulated in the RNA-Seq data. 
 
The gene for Myc-induced nuclear antigen (MINA) was chosen as it is a direct target gene 
of Myc, interacting through an E-box site in the genes promoter. MINA mRNA and 
protein levels are reduced in response to a reduction in Myc protein levels [132]. MINA 
has been shown to play an important role in cellular proliferation and is overexpressed in 
many cancer types indicating it may be involved in carcinogenesis and tumour 




also chosen. It is also directly regulated by Myc through activation of an E-box element 
in its promoter [137]. Both these genes would be expected to be down-regulated in 
response to a decreased Myc level. 
 
A third direct Myc target, CDKN1A, is a Cyclin-dependent kinase inhibitor (p21) which 
can bind a variety of cyclin-dependent kinases, functioning as a regulator of cell cycle 
progression and mediating cellular senescence [138]. Myc directly interacts with the 
CDKN1A promoter via recruitment by the DNA binding protein Miz-1, blocking 
activation by p53, p73 and other activators and inhibiting transcription [139, 140]. Myc 
inhibition would therefore be predicted to result in an increase in transcription of this 
gene. 
 
The fourth gene chosen, CCND1, encodes Cyclin D1, a regulatory subunit of the cyclin-
dependent kinases CDK4 and CDK6, which are required for progression through the G1 
phase of the cell cycle [141]. There is evidence that Myc can repress transcription of 
CCND1 [142]. Myc inhibition would therefore be expected to down-regulate CCND1 
expression. Fibroblasts lacking D-type cyclins 1-3 are unable to be transformed by Myc 
suggesting an important role for D-type cyclins in Myc-mediated transformation [143]. 
 
As well as downstream targets, Myc mRNA levels were also quantified. Myc has a 
negative autoregulation mechanism resulting in transcription being repressed in response 
to Myc-Max heterodimers [144]. Myc sequestration should result in less Myc-Max 





5.5.2 qRT-PCR confirms RNA-seq data on selected downstream Myc targets in 
1746-Omomyc treated cells 
T11 cells were treated with 1746-Omomyc, Penetratin-Omi, Mutant Penetratin-Omi and 
controls and qRT-PCR was carried out using probes for the selected Myc target genes. 
The results from the 1746-Omomyc treated cells confirmed the data from the RNA-Seq 
analysis and is consistent with Myc inhibition. The direction of regulation was the same 
for all genes tested; however all genes were either up or down-regulated to a greater extent 
in the RNA-Seq analysis than was seen with qRT-PCR (Table 6). Myc and CDKN1A 
mRNA levels were substantially upregulated to 1.63 and 4.87 fold compared to the 
control cells, while CCND1, MINA and E2F2 levels were substantially down-regulated 
with 0.34, 0.39 and 0.70 fold expression compare to the control (Figure 10). 
  Table 6: Comparison of RNA-Seq and qRT-PCR expression 
  data on Myc targets in T11 cells treated with 1746-Omomyc 
  at 5µM for 3 hours. Data are fold change relative to untreated 






Myc 2.59 1.63 
Cdkn1A 8.03 4.87 
MINA 0.34 0.39 
E2F2 0.39 0.70 
CCND1 0.19 0.34 
 
5.5.3 Expression of Myc targets consistent with Myc inhibition 
The regulation of Myc targets was consistent with Myc inhibition with up-regulation of 
Myc and CDKN1A, and down-regulation of MINA and CCND1 in response to 1746-
Omomyc, Penetratin-Omi and Mutant Penetratin-Omi (Figure 10). E2F2, however was 





Although Myc levels were higher in the Mutant Penetratin-Omi treated cells, the 
responses of the other Myc target genes were similar for Penetratin-Omi and Mutant 
Penetratin- Omi treated cells. 
  
 
Myc was upregulated to 2.92 fold in Penetratin-Omi and 4.70 fold in Mutant Penetratin-
Omi treated cells. CDKN1A was substantially upregulated to 3.61 fold for Penetratin-Omi 
and 3.39 fold for the Mutant treated cells. MINA was down-regulated to 0.48 fold for 
Penetratin-Omi and 0.50 fold for the mutant. CCDN1A was also down-regulated to 0.70 
fold for Penetratin-Omi and 0.61 fold for the Mutant. E2F2 was not substantially 
downregulated as was seen in the 1746 and 1746-Omomyc treated cells but remained 
close to what was expressed in the control with 1.10 fold expression in Penetratin-Omi 
and 1.00 fold expression in the Mutant treated cells. The direction of regulation of four 


































mRNA expression of downstream Myc targets
MYC CDKN1A MINA CCND1 E2F2
Figure 10: mRNA levels of selected downstream Myc targets determined by qRT-PCR 
in T11 cells. Cells were treated with 1746-Omomyc, 1746 and Omomyc at 5µM and 
Penetratin-Omi and Mutant Penetratin-Omi at 50µM for 3 hours. Calculated using the 
Delta Delta Ct method with GAPDH as the reference gene and normalised to expression 




as was seen for 1746-Omomyc (all except E2F2). With the exception of Myc the changes 
were substantially greater in the 1746-Omomyc treated cells however. 
 
The expression of E2F2 was very similar in 1746-Omomyc and 1746 treated cells (0.70 
and 0.66 Fold) and was not downregulated in the Penetratin-Omi and Mutant Penetratin-
Omi treated cells. 1746 treated cells showed elevated Myc expression (1.21 fold) and 









































These results reveal the use of 1746-Omomyc as a promising strategy for inhibition of 
Myc in TNBC. It inhibited the growth of several TNBC cell lines at reasonably low 
concentrations via a reduction in cellular proliferation. The results were consistent with 
other studies utilising Omomyc in which a marked reduction in proliferation was seen [6, 
145]. Omomyc shows great potential as a Myc inhibitor and anti-cancer agent. It has 
several benefits that come with using a protein based inhibitor, including a potentially 
high affinity and specificity for its target and low potential for toxicity.  This work shows 
that the 1746 CPP was successful at delivering Omomyc into the cell while maintaining 
its therapeutic activity. The CPP-peptide conjugates also displayed some selectivity 
toward cancer cells over non-cancerous cell lines; a property which may make them 
useful for the delivery of other cancer targeted therapies and worthy of further 
investigation. A significant loss of activity and change in mechanism of action was seen 
with the truncated peptide conjugates. Further investigation into their design is likely to 
be beneficial in improving their activity and reducing the concentrations required. 
 
6.1 Myc levels in cell panels 
In both the murine and human cell lines tested the highest Myc expression was seen in a 
cell line of the claudin-low subtype. Although the Myc levels in the basal-like cell lines 
were not much lower in the murine panel; in the human panel the SUM159 cells had 
substantially higher levels of Myc. This was in contrast to other studies which have 
characterised claudin-low tumours as typically having lower Myc expression than the 





The increased expression of Myc in T11 cells was modest at only 1.35 fold the expression 
seen in the NIH-3T3 cells. As NIH-3T3s are an immortalised cell line it should be noted 
that there is a possibility that it may also overexpress Myc. It must also be considered that 
mRNA levels often do not correlate with protein level. Post-transcriptional processes 
contribute greatly to the final amount of protein present and can work in amplification or 
competition with transcriptional signals [147]. It would therefore be advantageous to also 
quantify the level of the Myc protein in each cell line. 
 
The T11 cell line is deficient in the tumour suppressor p53. p53 is mutated in a large 
proportion of human breast cancers and is especially prominent in tumours of the basal-
like subtype and in BRCA1-mutated tumours [148]. The p53 mutation also acts as a 
marker indicative of poor prognosis and chemotherapy resistance [149]. Gene expression 
analyses suggest that this model may mimic human tumours more closely than many other 
models [18, 150]. For these reasons, T11 cells were chosen as a model for subsequent 
experiments. 
 
6.2 Variability in response to 1746-Omomyc 
A correlation of the response to the 1746-Omomyc peptide and the Myc mRNA level in 
the human panel was found. This analysis was based on very limited experimental results 
as Myc levels were only quantified once for each cell line and only a small number of cell 
lines were tested. This could be improved by adding more cell lines and replicating the 
results. An R2 value of 0.718 (SE 0.230) for this model indicates that a substantial 
proportion of the difference in response to the peptide may be accounted for by the cells’ 




variability in the response to this treatment. These could include cell division time, tumour 
subtype and membrane composition. 
 
The cell division time of each cell line was not considered and results were read after a 
fixed time of 24 hours. Slower dividing cell lines may be responding well to the treatment, 
but this may not equate to a large percentage of inhibition compared to the controls in 
only 24 hours. This may be a confounding factor that should be considered in future 
studies. It would be useful to compare cell lines with similar cell division times, but large 
differences in Myc levels. 
 
It is also of interest whether there is any correlation between the response to the treatment 
and the tumour subtype. In the human panel there does appear to be a correlation of 
response to the 1746-Omomyc peptide and the breast cancer subtype with claudin-low 
and basal-like tumours showing the greatest response and the luminal tumours a lesser 
response. More data would be needed to draw any definitive conclusions. This trend 
doesn’t appear to be based entirely on the level of Myc expressed in the cells. For example, 
the response to the peptide was significantly different for the luminal ZR-75-1 cells and 
the basal-like SUM149 cells although the Myc levels measured were similar. The 
complexity of Myc regulation and the heterogeneity of breast cancer leave a large window 
for differences in response to a Myc inhibitor. Some cancer types may have a genetic 
program making them more dependent on Myc amplification than other types for 
proliferation. This may be more likely in basal-like tumours as a core Myc gene 
expression signature has been found to be more prominent in basal-like cancers than in 




of stem-cell like features in claudin-low tumours, it is possible that the claudin-low cell 
lines tested were also highly dependent on Myc amplification for proliferation. 
 
As the uptake of CPPs is dependent on electrostatic interactions, the membrane 
composition of each cancer cell population is likely also a driving factor in the variability 
of response to 1746-Omomyc. Cells with more negatively charged components on the 
cell membrane may favour the uptake of the positively charged peptide.  
 
6.3 Mechanism of action 
A reduction in cell viability was not seen in T11 cells when treated with 1746 or 
Omomyc alone. This was expected as the unconjugated Omomyc peptide is unable to 
penetrate the cell unaided. Cell viability was greatly reduced however when treated with 
the 1746-Omomyc conjugate. This suggests that 1746-Omomyc is being successfully 
delivered into the cells. The lack of response to the free 1746 CPP suggests that the 
inhibition of the cells, when treated with the 1746-Omomyc peptide, is due to the cargo 
(Omomyc) rather than the CPP itself. 
 
The results of the Ki-67 and Annexin V and Propidium Iodide assays taken together 
indicate that the reduction in the number of viable T11 cells treated with the 1746-
Omomyc peptide is caused primarily by a reduction in the number of proliferating cells, 
rather than through cell death. In contrast, the results of these assays indicate that the 
primary cause of the reduction in the number of viable cells after treatment with the 
Penetratin-Omi and Mutant Penetratin-Omi peptides is through cell death rather than 





The primary mechanism of action of 1746-Omomyc (reduced proliferation) is in accord 
with the mechanism of action of Omomyc in which reduced proliferation and cell cycle 
arrest have been reported [6, 145]. Other studies on Omomyc have reported its ability to 
induce cell death via apoptosis [95, 145]. The mechanism of cell death (apoptosis or 
necrotic pathways) could not be determined from the Annexin V/PI assay as it was only 
carried out after treatment at a single time point but could be determined by tracking the 
changes in each population of cells over multiple time points. 
 
6.4 Increased IC50 for 1746-Omi 
The protein-protein interaction between Myc and Omomyc is dependent on the proteins’ 
secondary structure. The average length of a helical domain in a protein is small, spanning 
only two to three helical turns (eight to twelve residues), suggesting the possibility of 
developing short but biologically relevant alpha helical peptides [151]. The organisation 
into the helical structure is energetically demanding however [152]. Once a peptide is 
excised from a parent protein they often adopt an ensemble of shapes reducing their 
ability to specifically bind their intended target and increasing their susceptibility to 
proteases[153]. 
 
The destabilisation of conformation in the case of the shorter peptide is one possible 
explanation for the great reduction in potency between 1746-Omomyc and 1746-Omi. 
Several strategies have been developed for the stabilisation of short peptide sequences 
into helices. These include non-natural amino acid substitutions, helix capping, side chain 
constraints and hydrogen bond surrogates [154-157]. One or more of these strategies may 





Another factor that may have contributed to the decreased activity in the shorter CPP 
conjugates is the lack of a linker between the CPP and cargo domains. The 1746-Omomyc 
peptide contains a short 3 amino-acid linker (GAS). It has been shown that the absence 
of a suitable linker can lead to protein misfolding or impaired biological activity [158-
160]. Most natural multi-domain proteins have a linker sequence with the average length 
being 6.5 amino acids long [161]. The investigation and inclusion of a suitable linker in 
the shorter CPP conjugates could be beneficial in improving the biological activity of the 
peptides. 
 
6.5 Greater response for Penetratin-Omi than 1746-Omi 
Penetratin-Omi was found to have greater activity than 1746-Omi at a range of 
concentrations tested. This could be due to the reduced internalisation of the peptide or 
decreased biological activity once inside the cell. There are several factors that may 
contribute to differences in internalisation including the peptides size, charge, secondary 
structure and amino acid composition. 
 
Penetratin-Omi is smaller in size than 1746-Omi, with 44 amino acids compared to 66 
amino acids, respectively. Although an increased size may affect penetrability, there are 
other factors that are likely more important. Due to the negative charge of cell membranes 
the charge of a CPP is an important factor in internalisation. 1746-Omi has a greater net 
positive charge at 17.1 than Penetratin-Omi at 7.1. However, the greater charge did not 
lead to greater activity in this case.  There are other differences between the peptides that 
may affect their internalisation or activity. 1746 is lysine rich whilst Penetratin also 
contains critical arginine residues. This may cause differences in the mechanism of 




oligoarginine based CPPs compared to polylysine-based ones [109]. CPPs are often 
classified based on their amphipathicity as this also plays an important role in the 
mechanism of CPP membrane binding.  Strong hydrophobic interactions are observed for 
amphipathic, but not for cationic CPPs [109].  Penetratin is considered a secondary 
amphipathic peptide as it contains a hydrophobic side and a cationic side only when in an 
alpha-helical conformation. Penetratin contains several hydrophobic amino acids, having 
a hydrophobicity score at pH 6.8 of 23. 1746 has quite different properties; is a cationic 
CPP made up almost entirely of hydrophilic amino acids with a hydrophobicity score at 
pH 6.8 of -22.74.  Some of the properties of the CPPs are summarised in Table 7. 
 











1746 Sequence unable to be disclosed 17.0 -22.74 4.538 
Penetratin RQIKIWFQNRRMKWKK 7.0 23.00 2.247 
To calculate net charge acidic amino acid residues are assigned a value of 1, basic amino acid residues -1 and neutral amino acid 
residues 0. Hydrophobicity at pH 6.8 calculated using BioSynthesis Peptide Property Calculator version 3.1 
 
Investigating the level of peptide internalisation would also be useful in determining if 
the difference in activity between the two peptides was due to a lower biological activity 
or a reduced internalisation efficiency. This can be challenging however, as studies have 
shown that the conjugation of a fluorophore or ligand often produces confounding effects 
that may alter the internalisation, toxicity or functioning of a CPP [162, 163]. This was 
seen with the FITC labelled 1746 CPP. The increased toxicity demonstrates the difficulty 
faced in easily assessing internalisation of CPPs and indicates that FITC labelling is an 





6.6 Cancer Selectivity 
Both 1746-Omi and Penetratin-Omi showed complete selectivity towards the tumorigenic 
T11 cells over the non-tumorigenic NIH-3T3 cell line which showed no decrease in cell 
viability even at a concentration of 50µM. This may be partially attributed to differences 
in the charge of the cells. Due to changes in metabolism, cancer cells are known to have 
a more negative surface charge than non-tumorigenic cells [164, 165]. Since both peptides 
are positively charged, electrostatic interactions would favour the interaction of these 
peptides with the tumorigenic cells. This result was consistent with other studies in which 
other alpha-helical membrane-active proteins have shown specificity towards cancer cells 
[166]. Interestingly, this cancer cell selectivity was not as strong with 1746-Omomyc, 
despite 1746-Omomyc also having a large positive net charge, with some reduction in 
cell viability evident in NIH-3T3 cells at only 1µM. The hydrophobicity of alpha-helical 
peptides has also been shown to be an important factor in membrane interactions with 
anti-cancer activity being correlated with peptide hydrophobicity [166]. 
 
6.7 Mutant Penetratin-Omi 
In the Mutant Penetratin-Omi peptide, alanine was used to replace the four amino acids 
that are critical in Omomyc’s binding to Myc. Alanine was chosen as it is chemically inert 
being non-polar and having a non-bulky methyl functional group that is non-reactive and 
rarely involved in protein function [167]. Alanine also has a high propensity for helix 
formation and would not be expected to hinder the formation of the peptides secondary 
structure [168]. Interestingly, the Mutant Penetratin-Omi also significantly reduced cell 
viability in T11 cells. There are several possibilities that could explain this result. It is 




with Myc. It may be more suitable to use charged amino acids for some of the critical 
substitutions.  
 
6.8 Cargo dependent Cytotoxicity? 
Another possibility is that Penetratin-Omi and Mutant peptides are wholly or partially 
reducing cell viability through another mechanism that is not based on Myc inhibition. 
The results of the proliferation and Apoptosis/Dead Cell Assays confirm that this is likely 
occurring to some extent because the primary mechanism of reduced cell viability was 
not through reduced proliferation as was seen for the 1746-Omomyc peptide but rather 
through cell death. It is possible that a cargo-dependent cytotoxicity of the CPP-
conjugates is occurring at the higher concentrations tested. There was no reduction in cell 
viability when treated with free Penetratin up to the maximum concentration tested of 
50µM. This is in accord with other studies. Penetratin is generally thought to be non-toxic 
and has been shown not to significantly decrease cell viability even at concentrations up 
to 100µM [169]. However, the cytotoxicity of a CPP has been shown to vary depending 
on its context and is highly dependent on the attached cargo [162]. Cargo dependent 
cytotoxicities have been reported for Penetratin-peptide conjugates. This can be seen in a 
study of the effect of a peptide targeting pancreatic cancer cells in which addition of the 
penetratin sequence was shown to be responsible for a change in the mechanism of action, 
inducing necrosis rather than apoptosis, which was observed in Penetratin’s absence 
[170]. Due to the complexity of factors at play it is difficult to make comparisons between 
one study and another. 
 
To further investigate if this effect is due to the cargo or the CPP itself, it would be useful 




would be beneficial to include it in any future experiments. The Annexin V/Propidium 
Iodide assays should be repeated using multiple time points to gain a clearer 
understanding of whether the cell death was occurring primarily through apoptotic or 
necrotic pathways. 
 
6.9 Myc Inhibition 
Although the qRT-PCR analyses of the downstream Myc targets was able to confirm the 
results of the RNA-seq analysis for the selected genes, a full analysis of the Myc pathways 
from the RNA-seq data is needed to confirm Myc inhibition. Similarly, the qRT-PCR 
results on the Penetratin-Omi and Mutant Penetratin-Omi peptides suggest that a level of 
Myc inhibition may be occurring in response to the peptides, but RNA-seq would be 
needed to confirm this. 
 
The expression of the selected targets were affected similarly for Penetratin-Omi and 
Mutant Penetratin-Omi treated cells. This suggests they these two peptides are likely both 
working through the same mechanism of action. The same pattern of expression of the 
Myc targets was seen for the penetratin conjugated peptides as was seen for 1746-
Omomyc, although lower in magnitude (excluding Myc). This suggests that the 
mechanism of action of the Penetratin-Omi and Mutant Penetratin-Omi may in part be 
similar to the mechanism of the 1746-Omomyc peptide but with a lower level of activity. 
 
The similar expression of E2F2 in 1746-Omomyc and 1746 treated cells and lack of 
downregulation in the Penetratin-Omi and Mutant Penetratin-Omi treated cell indicate 





This data leaves open the possibility of a degree of Myc inhibition in response to both the 
Penetratin-Omi and Mut Penetratin-Omi, but does not confirm this. It would be of great 
value to include Penetratin as a control to rule out the changes caused by the CPP itself. 
As the experiment was only carried out a single time a statistical analysis of the 
differences between treatments is not possible. 
 
The upregulation of Myc transcription in response to the peptides was of interest as the 
negative autoregulation of the Myc gene has been shown to require the Myc-Max 
heterodimer [144]. This suggests that the interference of the formation of these dimers 
may have been successful. This result fits in with other studies which have confirmed that 
Myc expression is downregulated in response to the Myc protein [171]. There are, 
however, other critical pathways responsible for Myc regulation whose influence cannot 
be ruled out. 
 
CDKN1A was greatly upregulated in response to 1746-Omomyc as well as the penetratin-
conjugated peptides suggesting successful Myc inhibition. There are a variety of signals 
and factors that are involved in the transcriptional regulation of CDKN1A including the 
tumour suppresser p53 [172].  Some studies have reported the requirement of an intact 
p53 pathway for the treatment of cancer via Myc targeting [173]. This is of interest as the 
T11 cell line used in this study is a p53 null model. Interestingly, the induction of G1 
arrest by Omomyc has been found to be dependent on the activation of CDKN1A even in 
cancer cells with genetic TP53 inactivation [145]. This is thought to occur due to Myc’s 





Interestingly, 1746 treated cells also showed a degree of increased CDKN1A expression. 
This indicates that some of the increase in expression may also be attributable to a 
mechanism other than Myc inhibition. A degree of Myc-independent regulation is likely 
as this gene has been shown to be upregulated in response to a variety of stimuli [174]. 
This could be caused by the CPP itself or the entry of the peptide into the cell. 
 
The difference in expression in the other three genes was not as pronounced as was seen 
with Myc and CDKN1A. This is typical of gene expression studies involving Myc in 
which the average effect on expression of target genes is modest. 
 
6.10 Conclusions and Future Directions 
1746-Omomyc was successful in reducing cancer cell viability in triple-negative breast 
cancer cell lines overexpressing Myc at reasonably low concentrations. There was also 
some evidence of cancer selectivity with non-tumorigenic cell lines having a greatly 
reduced response to the peptide. This initial exploration of the mechanisms involved 
indicates that the reduction in cell viability is through reduced cellular proliferation rather 
than cell death and is consistent with Myc inhibition. Whether the cell death that is 
occurring is due to apoptotic or necrotic pathways could be further evaluated by repeating 
the Annexin V/PI Assay at multiple time points. 
 
A much higher concentration of the truncated version of the peptides (1746-Omi and 
Penetratin-Omi) was required to reduce cancer cell viability indicating that the biological 
activity of the cargo was greatly reduced. It may be beneficial to deduce the level of 




complexity of the effects of the CPPs themselves. This could be done by establishing a 
cell line with inducible Omi expression. 
 
There was evidence of cancer cell selectivity of Penetratin-Omi and 1746-Omi. If Omi is 
found to be biologically relevant, improvements in the design of the CPP conjugated 
peptides may increase the activity of the cargo. This could include further investigation 
into design mechanisms that aid in alpha helix stabilisation and the use of suitable linkers 
between the peptides two domains. 
 
A mutant version of the Penetratin-Omi peptide with critical amino acids involved in 
dimerization altered was also found to reduce cell viability, although not as significantly 
as the unaltered peptide. The primary mechanism of action of both peptides was found to 
be through cell death rather than reduced proliferation as was seen for 1746-Omomyc. 
Further investigation into the design of the mutant peptide would be useful to ensure it is 
not interacting with Myc. The possibility of a cargo dependent cytotoxicity occurring at 
the high concentrations that were needed to significantly reduce cell viability was 
uncovered. Increasing the activity of the peptide through the measures discussed above 
could reduce the peptide concentration required, reducing the chance of any potential 
cytotoxic side effects. Penetratin-Omi reduced cell viability in T11 cells significantly 
more than 1746-Omi at several concentrations tested. Due to the possibility of Penetratin-
Omi producing a cargo-dependent cytotoxicity, it would be useful to also determine the 
mechanism of action of the 1746-Omi peptide. 
 
qRT-PCR confirmed the results of an RNA-seq analysis on selected downstream Myc 




consistent with, but cannot confirm Myc inhibition in 1746-Omomyc, Penetratin-Omi 
and Mutant Penetratin-Omi treated cells. Myc inhibition could be confirmed via analysis 
of all Myc pathway genes using RNA-seq. 
 
Although more work is needed, the novel approach to Myc inhibition utilised in this study 
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Supplementary Figure 1: Dose response data of 1746 and FITC-1746 in T11 cells treated 
at concentrations from 0.25 to 50µM for 24 hours and cell viability assessed using CellTiter-
Glo Assays. Percentage of viable cells was normalised to non-treated control cells. All data 
points are presented as mean ± SEM for three independent experiments for 1746 and two 
independent experiments for FITC-1746. 
 
Supplementary Figure 2: Controls form Annexin V and Propicium Iodide Assay.  FACS 
analysis of T11 cells treated for 24 hours with 1746 at 2.5µM, Omomyc at 2.5µM, Penetratin 
at 25µM and no treatment (control) stained with FITC-Annexin V and Propidium Iodide. 
